A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions.

Trial Profile

A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Clopidogrel (Primary) ; Prasugrel (Primary) ; Aspirin
  • Indications Coronary artery disease; Coronary stent thrombosis; Myocardial infarction; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DAPT
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 22 Feb 2017 Results (n=11648) assessing myocardial infarction risk after discontinuation of Thienopyridine in the randomized DAPT study, published in the Circulation.
    • 30 Aug 2016 Post hoc analysis (N=11643) published in the Circulation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top